We measured the proportion of primary prostate cancer-derived 22Rv-1 cells that simultaneously expressed that surface markers CD44 and CD133, which have been shown to contain the enriched CSCs in PAC (46, 47). This evidence concerns the gene CD44 and prostate carcinoma.